SNC-115 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Neuroendocrine Carcinoma. According to GlobalData, Phase I drugs for Neuroendocrine Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SNC-115 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNC-115 overview

SNC-115 is under development for the treatment of recurrent and refractory small cell lung cancer and lung large cell neuroendocrine carcinoma. The therapeutic candidate comprises allogenic NK cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing tumor associated antigens acts by targeting cells expressing delta like protein 3 (DLL3). It is administered through parenteral route.

Shanghai Simnova Biotechnology overview

Shanghai Simnova Biotechnology is a clinical cell therapy platform company. It is headquartered in Shanghai, China.

For a complete picture of SNC-115’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.